4 Stocks Pushing The Drugs Industry Higher

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

Two out of the three major indices are trading lower today with the Dow Jones Industrial Average (^DJI) trading down 39 points (-0.3%) at 13,960 as of Monday, Feb. 25, 2013, 11:49 AM ET. The NYSE advances/declines ratio sits at 1,475 issues advancing vs. 1,392 declining with 148 unchanged.

The Drugs industry currently sits down 0.7% versus the S&P 500, which is down 0.1%. Top gainers within the industry include Gilead (GILD), up 1.3%, Novartis (NVS), up 0.6% and Novo Nordisk A/S (NVO), up 0.6%. On the negative front, top decliners within the industry include GlaxoSmithKline (GSK), down 1.2%, and Celgene Corporation (CELG), down 0.8%.

TheStreet Ratings group would like to highlight 4 stocks pushing the industry higher today:

4. Perrigo Company (PRGO) is one of the companies pushing the Drugs industry higher today. As of noon trading, Perrigo Company is up $3.44 (3.0%) to $116.75 on average volume Thus far, 458,077 shares of Perrigo Company exchanged hands as compared to its average daily volume of 786,700 shares. The stock has ranged in price between $115.30-$116.90 after having opened the day at $115.71 as compared to the previous trading day's close of $113.31.

Perrigo Company, through its subsidiaries, develops, manufactures, and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, and active pharmaceutical ingredients (API) worldwide. Perrigo Company has a market cap of $10.7 billion and is part of the health care sector. The company has a P/E ratio of 24.6, above the S&P 500 P/E ratio of 17.7. Shares are up 9.2% year to date as of the close of trading on Friday. Currently there are 9 analysts that rate Perrigo Company a buy, 1 analyst rates it a sell, and 6 rate it a hold.

TheStreet Ratings rates Perrigo Company as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, growth in earnings per share, revenue growth, reasonable valuation levels and good cash flow from operations. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Perrigo Company Ratings Report now.

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE

1 2 3 4 Next › Last »

For more information on Amgen Inc click any of the following:

• Amgen Inc Stock Price

• Amgen Inc Analyst Ratings

• Amgen Inc Key Stats & Profile

• Amgen Inc Earnings

• Amgen Inc Ratio Comparison

• Amgen Inc Growth Rates

• Amgen Inc Balance Sheet

• Amgen Inc Cash Flow

• Amgen Inc Income Statement